Carbonic anhydrase inhibitors: inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with simple anions.

Bioorganic & Medicinal Chemistry Letters
Alessio InnocentiClaudiu T Supuran

Abstract

The catalytic activity and inhibition of the beta-carbonic anhydrases (CAs, EC 4.2.1.1) from the pathogenic fungi Candida albicans (Nce103) and Cryptococcus neoformans (Can2) with inorganic anions such as halogenides, pseudohalogenides, bicarbonate, carbonate, nitrate, nitrite, hydrogen sulfide, bisulfite, perchlorate, sulfate were investigated. The two enzymes showed appreciable CO(2) hydrase activity (k(cat) in the range of (3.9-8.0)x10(5)s(-1), and k(cat)/K(m) in the range of (4.3-9.7)x10(7)M(-1)s(-1)). Can2 was weakly inhibited by cyanide and sulfamic acid (K(I)s of 8.22-13.56 mM), while all other anions displayed more potent inhibition. Nce103 was strongly inhibited by cyanide and carbonate (K(I)s of 10-11 microM), and weakly inhibited by sulfate, phenylboronic, and phenyl arsonic acid (K(I)s of 14.15-30.85 mM). These data demonstrate that pathogenic, fungal beta-CAs may be targets for the development of antifungals that have a novel mechanism of action.

References

Oct 1, 1996·Clinical Microbiology Reviews·S K Fridkin, W R Jarvis
Mar 4, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J AbadiL Pirofski
Apr 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·T W Lane, F M Morel
Sep 9, 2000·FEMS Microbiology Reviews·K S Smith, J G Ferry
Nov 14, 2000·Journal of Bacteriology·K S SmithJ G Ferry
Nov 30, 2000·Current Infectious Disease Reports·W G Powderly
Apr 24, 2001·Protein Science : a Publication of the Protein Society·J D CronkK Y Zhang
Nov 7, 2001·The Journal of Biological Chemistry·B C TrippJ G Ferry
Dec 25, 2002·Medicinal Research Reviews·Claudiu T SupuranAngela Casini
Nov 13, 2003·Bioorganic & Medicinal Chemistry Letters·Marco FranchiClaudiu T Supuran
Dec 25, 2003·Journal of Enzyme Inhibition and Medicinal Chemistry·Daniela VulloClaudiu T Supuran
Sep 29, 2004·FEMS Yeast Research·Guilhem Janbon
Sep 30, 2004·Bioorganic & Medicinal Chemistry Letters·Alessio InnocentiClaudiu T Supuran
Nov 18, 2004·Bioorganic & Medicinal Chemistry Letters·Sabrina ZimmermanClaudiu T Supuran
Dec 28, 2004·Nature Structural & Molecular Biology·Clemens SteegbornHao Wu
Nov 24, 2005·Current Biology : CB·Torsten KlengelFritz A Mühlschlegel
Jan 10, 2006·Eukaryotic Cell·Estelle Geweiss MogensenFritz A Mühlschlegel
Oct 19, 2006·Current Opinion in Microbiology·Yong-Sun Bahn, Fritz A Mühlschlegel
May 4, 2007·Bioorganic & Medicinal Chemistry·Claudiu T Supuran, Andrea Scozzafava
May 17, 2007·Current Topics in Medicinal Chemistry·Sabrina A ZimmermanClaudiu T Supuran
Oct 2, 2007·Microbiology·Richard D CannonBrian C Monk
Jan 3, 2008·Nature Reviews. Drug Discovery·Claudiu T Supuran
Mar 14, 2008·Current Pharmaceutical Design·Claudiu T Supuran

❮ Previous
Next ❯

Citations

Jun 21, 2012·Applied Biochemistry and Biotechnology·Bashistha Kumar KanthSeung Pil Pack
Apr 24, 2013·Applied Biochemistry and Biotechnology·Abhishek BhattacharyaAnjana Sharma
Aug 3, 2011·Future Medicinal Chemistry·Claudiu T Supuran
May 6, 2014·Bioorganic & Medicinal Chemistry·Isao NishimoriClaudiu T Supuran
Mar 16, 2013·Expert Opinion on Therapeutic Patents·Clemente Capasso, Claudiu T Supuran
Dec 17, 2008·Journal of Molecular Biology·Christine SchlickerClemens Steegborn
Feb 6, 2017·Plant Physiology and Biochemistry : PPB·Jolanta Floryszak-Wieczorek, Magdalena Arasimowicz-Jelonek
Jan 25, 2018·Journal of Enzyme Inhibition and Medicinal Chemistry·Daniela VulloClaudiu T Supuran
Oct 20, 2019·International Journal of Molecular Sciences·Ashok AspatwarSeppo Parkkila
Dec 22, 2017·Environmental Science and Pollution Research International·Shazia Faridi, Tulasi Satyanarayana
Oct 10, 2009·Molecular Biology Reports·Michael K FasseasPanagiotis Katinakis
Aug 4, 2015·Expert Opinion on Therapeutic Targets·Clemente Capasso, Claudiu T Supuran
Jul 28, 2019·Applied Microbiology and Biotechnology·Bart PanderAnne M Henstra
Feb 18, 2010·Journal of Medicinal Chemistry·Pascale JosephClaudiu T Supuran
Feb 22, 2011·Journal of Medicinal Chemistry·Rohan A DavisSally-Ann Poulsen
Jul 4, 2009·Bioorganic & Medicinal Chemistry Letters·Alessio InnocentiClaudiu T Supuran
Aug 15, 2009·Biochimica Et Biophysica Acta·Roger S Rowlett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.